Results 61 to 70 of about 27,659 (185)
ABSTRACT Background The prognostic benefit of revascularization for unprotected left main (LM) disease remains uncertain, as guideline endorsement of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) precludes comparison with deferral, which is unlikely to be assessed in a randomized trial.
Marc Meller Bröchner +10 more
wiley +1 more source
P2Y12 inhibitor use predicts hematoma expansion in patients with intracerebral hemorrhage
Objective Hematoma expansion (HE) predicts disability and death after acute intracerebral hemorrhage (ICH). Aspirin and anticoagulants have been associated with HE. We tested the hypothesis that P2Y12 inhibitors predict subsequent HE in patients.
Ethan J. Houskamp +6 more
doaj +1 more source
It remains unknown whether the recent trend of short dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy can simply be applied to patients undergoing complex percutaneous coronary intervention (PCI).
Yohei Sotomi +11 more
doaj +1 more source
Polimorfisme P2Y12 Terhadap Agregasi Platelet Pada Pasien Penyakit Jantung Koroner
Genetic polymorphism of P2Y12 receptor is one of the factors responsible for the variation in response to antiplatelet therapy. Variations in response to P2Y12 receptors can cause Coronary Artheri Disease (CAD) in CHD patients.
hermawatiningsih, oktaviarika dewi
core +1 more source
ABSTRACT The identification of the “culprit lesion” in acute coronary syndromes (ACS) traditionally relies on coronary angiography, assuming that the most severe stenosis, abrupt occlusion, or largest filling defect marks the site of plaque destabilization.
Fernando Quevedo‐Candela +7 more
wiley +1 more source
Novel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel.
van Werkum, JW +10 more
core +1 more source
Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry [PDF]
Background Early escalation from clopidogrel to new generation P2Y12 inhibitors is common practice in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).
Emanuele Meliga +33 more
core +1 more source
ABSTRACT Background RFR has shown good aggregate agreement with FFR, including in prior Asian cohorts using intracoronary nicorandil. Where RFR‐FFR disagreement is concentrated relative to the FFR 0.80 decision boundary, and how the two binary thresholds correspond, remain incompletely characterized. Methods In a prospective single‐center registry, 300
Yonghoon Shin +8 more
wiley +1 more source
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a fast
Martine Baumann +4 more
doaj +1 more source
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source

